期刊文献+

不同中医辨证分型胃癌细胞拓扑异构酶Ⅱ表达的实验研究 被引量:1

The Empirical Study of the DNAtopoll Expression of Differentiation of Symptoms and Signs for Classification of Syndrome of Gastric Carcinoma
下载PDF
导出
摘要 目的:检测不同证候类型胃癌细胞拓扑异构酶Ⅱ(topoⅡ)的表达。方法:原发性胃癌标本52例。中医辨证分为肝胃郁热型、脾胃虚寒型、瘀毒内阻型、痰湿凝结型,SP免疫组织化学染色检测拓扑异构酶Ⅱ的表达。结果:topoⅡ标记指数与胃癌中医辨证各分型均有明显相关性,其中以瘀毒内阻型topoⅡ表达最强。结论:说明瘀毒内阻型胃癌细胞对于DNA调节控制及细胞核内核酸代谢过程功能较强,同对各种肿瘤抗癌药物敏感性表现也较高。 Objective: To exam the DNAtopo Ⅱ expression of different syndrome of gastric carcinoma. Methods : There are 52 examples of syndrome of traditional Chinese medicine include stagnated heat type of liver and stomach, insufficiency of spleen-YANG, deficiency cold of the stomach,the internal resistance of poison, and the condense of phlegmatic hygrosis, sp immunohistochemistry stain detect the DNAtopo Ⅱ expression. Results : There are obviously dependability in the label indexes of topo Ⅱ and every traditional Chinese medicine groupings of gastric carcinoma, mostly expression in topo Ⅱ of the internal resistance of poison. Conclusion : To DNA controUability and the process of cell intranuclear liver nucleic acid metabolism,the gastric carcinoma ceils of the internal resistance of poison have more powerful ability, arid more sensitive to anticancer drugs of various kinds tumors.
出处 《中华中医药学刊》 CAS 2007年第2期349-350,共2页 Chinese Archives of Traditional Chinese Medicine
关键词 胃癌 拓扑异构酶Ⅱ gastric carcinoma DNA tope Ⅱ
  • 相关文献

参考文献4

  • 1[1]Katoh R.Bray CE,Suzuki K,et al.Growth activity in hyperplastic and neoplastic and neoplastic human thyroid determined by an immunohistochemical staining procedure using monoclonal antibody MIB-1[J].Humpathol,1995,26:139-146
  • 2[2]Schneider E,Hsiang YH,LiuLu,DNA topoisonerses as anticancer drug targets[J].Adv Pharmacol,1990,21;149-183
  • 3张声,陈林莺,李莉,曾赛凡,陈余朋.拓扑异构酶Ⅱ在胃癌中的表达[J].福建医科大学学报,2000,34(2):132-134. 被引量:6
  • 4齐元富,钱伯文,陈伟,张永祥.41例胃癌兼挟血瘀证的临床研究[J].辽宁中医杂志,1995,22(2):70-71. 被引量:8

二级参考文献14

  • 1陈可冀,李连达,翁维良.血瘀证与活血化瘀研究[J].中西医结合心脑血管病杂志,2005,3(1):1-2. 被引量:238
  • 2Schneider E,Hsiang YH,Liu LF.DNAtopoisomerases as anticancer drug targets[J].Adv Pharmacol,1990,21:149~183.
  • 3Katoh R,Bray CE,Suzuki K,et al.Growth activity in hyperplastic and neoplastic humanthyroid determined by an immunohistochemical staining procedure using monoclonal antibodyMIB-1[J].Hum Pathol,1995,26:139~146.
  • 4Drake FH,Hofmann GA,Bartus HF,et al.Biochemical and pharmacological properties ofp170 and p180 forms of topoisomerase Ⅱ[J].Biochemistry,1989,28:8154~8160.
  • 5Fry AM,Chresta CM,Davies SM,et al.Relationship between topoisomerase Ⅱ level andchemosensitivity in human tumor cell lines[J].Cancer Res,1991,51:6592~6595.
  • 6Uemura T,Ohkura H,Adachi Y,et al.DNA topoisomerase Ⅱ is required for condensationand separation of mitotic chromosomes in S.Pombe[J].Cell,1987,50:917~925.
  • 7Kaufmann SH,McLaughlin SJ,Kastan MB,et al.Topoisomerase Ⅱ levels duringgranulocytic maturation in vitro and in vivo[J].Cancer Res,1991,51:3534~3543.
  • 8Kasahara K,Fujiwara Y,Sugimoto Y,et al.Determinants of response to the DNAtopoisomerase Ⅱ inhibitors doxorubicin and etoposide in human lung cancer lines[J].JNatl Cancer Inst,1992,84:113~118.
  • 9Nitiss JL,Liu YX,Harbury P,et al.Amsacrine and etoposide hypersentivity of yeastcells overexpressing DNA topoisomerase Ⅱ[J].Cancer Res,1992,52:4467~4472.
  • 10Oya M,Yao T,Nagai F,et al.Metastasizing intramucosal gastric carcinomas:welldifferentiated type and proliferative activity using proliferative cell nuclear antigenand ki-67[J].Cancer,1995,75:926~935.

共引文献12

同被引文献27

引证文献1

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部